Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Novel Insights Into the Interaction Between Long Non-Coding Rnas and Micrornas in Glioma Publisher Pubmed



Ebrahimpour A1 ; Sarfi M2, 3 ; Rezatabar S1 ; Tehrani SS2, 3
Authors

Source: Molecular and Cellular Biochemistry Published:2021


Abstract

Glioma is the most common brain tumor of the central nervous system. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have been identified to play a vital role in the initiation and progression of glioma, including tumor cell proliferation, survival, apoptosis, invasion, and therapy resistance. New documents emerged, which indicated that the interaction between long non-coding RNAs and miRNAs contributes to the tumorigenesis and pathogenesis of glioma. LncRNAs can act as competing for endogenous RNA (ceRNA), and molecular sponge/deregulator in regulating miRNAs. These interactions stimulate different molecular signaling pathways in glioma, including the lncRNAs/miRNAs/Wnt/β-catenin molecular signaling pathway, the lncRNAs/miRNAs/PI3K/AKT/mTOR molecular signaling pathway, the lncRNAs-miRNAs/MAPK kinase molecular signaling pathway, and the lncRNAs/miRNAs/NF-κB molecular signaling pathway. In this paper, the basic roles and molecular interactions of the lncRNAs and miRNAs pathway glioma were summarized to better understand the pathogenesis and tumorigenesis of glioma. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.
Other Related Docs
8. Long Non-Coding Rnas As Epigenetic Regulators in Cancer, Current Pharmaceutical Design (2019)
13. Exosomal Noncoding Rnas: Key Players in Glioblastoma Drug Resistance, Molecular and Cellular Biochemistry (2021)
14. Exosomes and Micrornas in Biomedical Science, Synthesis Lectures on Biomedical Engineering (2022)
17. Modulation of Cancer Cell Signaling by Long Noncoding Rnas, Journal of Cellular Biochemistry (2019)
20. How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer, International Immunopharmacology (2020)